SYRE

Spyre Therapeutics, Inc.

Price Chart

Latest Quote

$88.34

+0.85 (+0.97%)

Current Price

Previous Close	$87.49
Open	$89.55
Day High	$90.99
Day Low	$86.22
Volume	1,965,671

Fetched: 2026-06-19T03:29:02

Stock Information

Shares Outstanding	86.84M
Cash Equivalents	$741.47M
Net Income	$-148.70M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$7.67B
EPS (TTM)	$-2.12
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$6.66B
Income	$-148.70M
Book/sh	$6.53
Cash/sh	$8.54
Employees	112

Financial Ratios

Quick Ratio	8.80
Current Ratio	8.97

Returns & Margins

ROA	-22.65%
ROE	-31.11%

Ownership

Insider Ownership	5.88%
Institutional Ownership	97.79%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-28.33
P/B	13.52

Analyst Data

Recommendation	strong_buy
Target Price	$99.13

Technical Indicators

SMA20	$76.67
SMA50	$72.73
SMA200	$40.89
RSI	68.77
ATR	4.9204

Shares Float	80.94M
Short Float	15.57%
Short Ratio	11.83
Volatility	3.06
Rel Volume	2.07

Performance History

Week	+9.37%
Month	+32.60%
Quarter	+108.79%
6 Months	+167.94%
YTD	+188.88%
Year	+481.95%
3 Years	+2460.58%
5 Years	-46.46%
10 Years	-20.95%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$88.34	2,283,112
2026-06-17	$87.49	1,537,200
2026-06-16	$83.41	1,337,100
2026-06-15	$83.58	1,156,400
2026-06-12	$80.79	958,600
2026-06-11	$80.77	1,267,900
2026-06-10	$75.08	981,300
2026-06-09	$76.44	1,593,100
2026-06-08	$72.00	1,036,000
2026-06-05	$73.65	1,479,800
2026-06-04	$78.48	1,118,900
2026-06-03	$73.52	1,679,700
2026-06-02	$69.16	814,300
2026-06-01	$70.54	921,800
2026-05-29	$73.50	1,113,800
2026-05-28	$72.11	429,000
2026-05-27	$72.51	558,000
2026-05-26	$73.65	478,400
2026-05-22	$74.05	574,900
2026-05-21	$74.32	738,600
2026-05-20	$71.92	1,088,200
2026-05-19	$66.62	1,385,700

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

📰 Latest News

SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up

Zacks • 2026-06-04T14:56:00Z

Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential

Insider Monkey • 2026-06-04T09:07:29Z

Why Spyre Therapeutics (SYRE) Is Down 6.1% After Broadening Its SPY003 Paragon License Terms

Simply Wall St. • 2026-06-02T22:07:24Z

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

Motley Fool • 2026-05-17T19:13:24Z

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

Motley Fool • 2026-05-17T19:01:48Z

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

Motley Fool • 2026-05-17T18:52:26Z

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

Motley Fool • 2026-05-17T18:42:28Z

Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer

Insider Monkey • 2026-05-05T17:05:19Z

Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million Raise

Simply Wall St. • 2026-05-01T19:09:06Z

Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?

Insider Monkey • 2026-04-30T13:57:28Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$886,000	$2,329,000
Operating Revenue	$0	$0	$886,000	$2,329,000
Expenses
Total Expenses	$219,562,000	$208,566,000	$129,450,000	$87,110,000
Other Income Expense	$39,459,000	$-20,713,000	$-216,399,000	$-7,000
Other Non Operating Income Expenses	$29,459,000	$-20,713,000	$-19,130,000	$-7,000
Net Non Operating Interest Income Expense	$24,885,000	$21,312,000	$6,147,000	$837,000
Operating Expense	$219,562,000	$208,566,000	$129,450,000	$87,110,000
General And Administrative Expense	$47,909,000	$45,776,000	$39,946,000	$28,531,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-155,203,000	$-208,018,000	$-338,790,000	$-83,815,000
Net Interest Income	$24,885,000	$21,312,000	$6,147,000	$837,000
Interest Income	$24,885,000	$21,312,000	$6,147,000	$837,000
Normalized Income	$-165,202,000	$-208,018,000	$-141,536,138	$-83,815,000
Net Income From Continuing And Discontinued Operation	$-155,203,000	$-208,018,000	$-338,790,000	$-83,815,000
Total Operating Income As Reported	$-209,562,000	$-208,566,000	$-242,303,000	$-84,781,000
Net Income Common Stockholders	$-155,203,000	$-208,018,000	$-338,790,000	$-83,815,000
Net Income	$-155,203,000	$-208,018,000	$-338,790,000	$-83,815,000
Net Income Including Noncontrolling Interests	$-155,203,000	$-208,018,000	$-338,790,000	$-83,815,000
Net Income Continuous Operations	$-155,203,000	$-208,018,000	$-338,790,000	$-83,815,000
Pretax Income	$-155,218,000	$-207,967,000	$-338,816,000	$-83,951,000
Special Income Charges	$10,000,000	$0	$-113,739,000	$0
Interest Income Non Operating	$24,885,000	$21,312,000	$6,147,000	$837,000
Operating Income	$-219,562,000	$-208,566,000	$-128,564,000	$-84,781,000
Per Share
Diluted EPS	$-1.98	$-3.18	$-13.76	$-24.75
Basic EPS	$-1.98	$-3.18	$-13.76	$-24.75
Other
Tax Effect Of Unusual Items	$1,000	$0	$-15,138	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-229,562,000	$-208,566,000	$69,449,000	$-82,817,000
Total Unusual Items	$10,000,000	$0	$-197,269,000	$0
Total Unusual Items Excluding Goodwill	$10,000,000	$0	$-197,269,000	$0
Reconciled Depreciation	$0	$0	$744,000	$1,964,000
EBITDA (Bullshit earnings)	$-219,562,000	$-208,566,000	$-127,820,000	$-82,817,000
EBIT	$-219,562,000	$-208,566,000	$-128,564,000	$-84,781,000
Diluted Average Shares	$64,056,442	$47,027,638	$6,897,065	$3,371,231
Basic Average Shares	$64,056,442	$47,027,638	$6,897,065	$3,371,231
Diluted NI Availto Com Stockholders	$-155,203,000	$-208,018,000	$-338,790,000	$-83,815,000
Tax Provision	$-15,000	$51,000	$-26,000	$-136,000
Gain On Sale Of Ppe	$10,000,000	$0	$16,449,000	$0
Research And Development	$171,653,000	$162,790,000	$89,504,000	$58,579,000
Selling General And Administration	$47,909,000	$45,776,000	$39,946,000	$28,531,000
Other Gand A	$47,909,000	$45,776,000	$39,946,000	$28,531,000
Preferred Stock Dividends	-	$58,463,000	$243,907,000	-
Other Special Charges	-	-	$130,188,000	-
Gain On Sale Of Security	-	-	$-83,530,000	-

Fetched: 2026-06-14

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$715,236,000	$517,804,000	$184,016,000	$50,305,000
Total Assets	$777,781,000	$608,484,000	$341,859,000	$71,144,000
Total Non Current Assets	$0	$10,000	$331,000	$8,886,000
Current Assets	$777,781,000	$608,474,000	$341,528,000	$62,258,000
Other Current Assets	$21,248,000	$5,386,000	$2,251,000	$6,172,000
Cash Cash Equivalents And Short Term Investments	$756,533,000	$603,088,000	$339,277,000	$55,711,000
Cash And Cash Equivalents	$85,721,000	$89,423,000	$188,893,000	$34,863,000
Other Non Current Assets	-	$10,000	$331,000	$2,236,000
Receivables	-	-	$0	$375,000
Other Receivables	-	-	-	$375,000
Prepaid Assets	-	-	-	-
Debt
Total Debt	-	-	$0	$4,629,000
Long Term Debt And Capital Lease Obligation	-	-	$0	$4,004,000
Current Debt And Capital Lease Obligation	-	-	-	$625,000
Liabilities
Total Liabilities Net Minority Interest	$62,545,000	$90,680,000	$157,843,000	$20,839,000
Total Non Current Liabilities Net Minority Interest	$3,860,000	$36,620,000	$125,865,000	$6,183,000
Other Non Current Liabilities	$3,860,000	$36,620,000	$41,310,000	-
Current Liabilities	$58,685,000	$54,060,000	$31,978,000	$14,656,000
Other Current Liabilities	$22,999,000	$25,581,000	$1,878,000	$330,000
Payables And Accrued Expenses	$27,746,000	$22,791,000	$26,046,000	$8,595,000
Payables	$8,918,000	$1,269,000	$17,480,000	$677,000
Accounts Payable	$8,904,000	$666,000	$896,000	$677,000
Non Current Deferred Liabilities	-	-	$0	$2,179,000
Current Deferred Liabilities	-	-	$0	$517,000
Equity
Common Stock Equity	$559,416,000	$361,984,000	$-911,000	$50,305,000
Preferred Stock Equity	$155,820,000	$155,820,000	$184,927,000	-
Total Equity Gross Minority Interest	$715,236,000	$517,804,000	$184,016,000	$50,305,000
Stockholders Equity	$715,236,000	$517,804,000	$184,016,000	$50,305,000
Gains Losses Not Affecting Retained Earnings	$869,000	$180,000	$302,000	$-48,000
Other Equity Adjustments	$869,000	$180,000	$302,000	$-48,000
Retained Earnings	$-1,127,635,000	$-972,432,000	$-764,414,000	$-425,624,000
Preferred Securities Outside Stock Equity	-	$0	$84,555,000	$0
Other
Ordinary Shares Number	$78,189,811	$60,257,023	$36,057,109	$2,614,013
Share Issued	$78,189,811	$60,257,023	$36,057,109	$2,614,013
Tangible Book Value	$559,416,000	$361,984,000	$-911,000	$50,305,000
Invested Capital	$559,416,000	$361,984,000	$-911,000	$50,305,000
Working Capital	$719,096,000	$554,414,000	$309,550,000	$47,602,000
Total Capitalization	$715,236,000	$517,804,000	$184,016,000	$50,305,000
Additional Paid In Capital	$1,686,167,000	$1,334,223,000	$763,191,000	$475,971,000
Capital Stock	$155,835,000	$155,833,000	$184,937,000	$6,000
Common Stock	$15,000	$13,000	$10,000	$6,000
Preferred Stock	$155,820,000	$155,820,000	$184,927,000	$0
Pensionand Other Post Retirement Benefit Plans Current	$7,940,000	$5,688,000	$4,054,000	$4,589,000
Current Accrued Expenses	$18,828,000	$21,522,000	$8,566,000	$7,918,000
Dueto Related Parties Current	$14,000	$603,000	$16,584,000	$0
Other Short Term Investments	$670,812,000	$513,665,000	$150,384,000	$20,848,000
Treasury Shares Number	-	-	$0	-
Capital Lease Obligations	-	-	$0	$4,629,000
Non Current Deferred Revenue	-	-	$0	$2,179,000
Long Term Capital Lease Obligation	-	-	$0	$4,004,000
Current Deferred Revenue	-	-	$0	$517,000
Current Capital Lease Obligation	-	-	$0	$625,000
Net PPE	-	-	$0	$6,650,000
Accumulated Depreciation	-	-	$0	$-4,144,000
Gross PPE	-	-	$0	$10,794,000
Leases	-	-	$0	$4,393,000
Machinery Furniture Equipment	-	-	$0	$714,000
Properties	-	-	$0	$0
Other Properties	-	-	-	$5,687,000

Fetched: 2026-06-14

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-169,252,000	$-157,410,000	$-99,910,000	$-80,182,000
Operating Activities
Operating Cash Flow	$-169,252,000	$-157,410,000	$-99,910,000	$-80,144,000
Cash Flow From Continuing Operating Activities	$-169,252,000	$-157,410,000	$-99,910,000	$-80,144,000
Operating Gains Losses	$-10,000,000	-	$198,184,000	$428,000
Investing Activities
Investing Cash Flow	$-143,475,000	$-353,285,000	$-108,393,000	$57,008,000
Cash Flow From Continuing Investing Activities	$-143,475,000	$-353,285,000	$-108,393,000	$57,008,000
Capital Expenditure	-	-	-	$-38,000
Financing Activities
Issuance Of Capital Stock	$311,132,000	$405,231,000	$366,474,000	$42,874,000
Financing Cash Flow	$309,025,000	$410,906,000	$361,077,000	$42,678,000
Cash Flow From Continuing Financing Activities	$309,025,000	$410,906,000	$361,077,000	$42,678,000
Net Other Financing Charges	$-5,413,000	$-1,836,000	$-5,802,000	-
Net Preferred Stock Issuance	$0	$168,850,000	$281,919,000	$0
Preferred Stock Issuance	$0	$168,850,000	$281,919,000	$0
Net Common Stock Issuance	$311,132,000	$236,381,000	$84,555,000	$42,874,000
Common Stock Issuance	$311,132,000	$236,381,000	$84,555,000	$42,874,000
Other
End Cash Position	$85,721,000	$89,423,000	$189,215,000	$36,416,000
Beginning Cash Position	$89,423,000	$189,215,000	$36,416,000	$16,980,000
Effect Of Exchange Rate Changes	$0	$-3,000	$25,000	$-106,000
Changes In Cash	$-3,702,000	$-99,789,000	$152,774,000	$19,542,000
Proceeds From Stock Option Exercised	$3,306,000	$7,511,000	$405,000	$222,000
Net Investment Purchase And Sale	$-150,475,000	$-353,285,000	$-126,903,000	$57,046,000
Sale Of Investment	$371,739,000	$245,967,000	$39,900,000	$96,546,000
Purchase Of Investment	$-522,214,000	$-599,252,000	$-166,803,000	$-39,500,000
Net Business Purchase And Sale	$0	$0	$3,035,000	$0
Sale Of Business	$0	$0	$3,035,000	$0
Net Intangibles Purchase And Sale	$7,000,000	$0	$15,000,000	$0
Sale Of Intangibles	$7,000,000	$0	$15,000,000	$0
Net PPE Purchase And Sale	$0	$0	$475,000	$-38,000
Sale Of PPE	$0	$0	$475,000	$0
Interest Received Cfo	$2,130,000	$1,283,000	$0	$0
Change In Working Capital	$-5,934,000	$-4,534,000	$-5,206,000	$-5,503,000
Change In Other Current Liabilities	$0	$0	$-2,326,000	$-435,000
Change In Payables And Accrued Expense	$6,885,000	$-1,602,000	$-7,075,000	$-3,484,000
Change In Accrued Expense	$-764,000	$14,609,000	$-4,891,000	$-843,000
Change In Payable	$7,649,000	$-16,211,000	$-2,184,000	$-2,641,000
Change In Account Payable	$7,649,000	$-16,211,000	$-2,184,000	$-2,641,000
Change In Prepaid Assets	$-12,819,000	$-2,932,000	$3,245,000	$-1,144,000
Change In Receivables	$0	$0	$375,000	$440,000
Other Non Cash Items	$-29,769,000	$20,430,000	$19,221,000	$426,000
Stock Based Compensation	$37,614,000	$44,833,000	$25,675,000	$7,111,000
Asset Impairment Charge	$0	$0	$2,580,000	$0
Amortization Of Securities	$-8,090,000	$-11,404,000	$-2,318,000	$-327,000
Depreciation Amortization Depletion	$0	$0	$744,000	$1,964,000
Depreciation And Amortization	$0	$0	$744,000	$1,964,000
Depreciation	$0	$0	$744,000	$1,964,000
Gain Loss On Sale Of PPE	$-10,000,000	$0	$114,654,000	$0
Net Income From Continuing Operations	$-155,203,000	$-208,018,000	$-338,790,000	$-83,815,000
Repayment Of Debt	-	$0	$-16,000	$-418,000
Net Issuance Payments Of Debt	-	$0	$-16,000	$-418,000
Net Long Term Debt Issuance	-	$0	$-16,000	$-418,000
Long Term Debt Payments	-	$0	$-16,000	$-418,000
Purchase Of PPE	-	$0	$0	$-38,000
Change In Other Working Capital	-	-	$575,000	$-880,000
Gain Loss On Investment Securities	-	-	$83,530,000	$428,000

Fetched: 2026-06-14